Dr. Lal Path Labs Ltd. Earnings Summary — Q4 FY2026
Dr. Lal Path Labs Reports Strong Q4 Recovery with 16.6% Revenue Growth and Net Profit Rebound
Key Takeaways
- Revenue grew 16.6% year-over-year to ₹703 crore in Q4 FY2026, driven by higher diagnostic volumes.
- Quarterly net profit saw a sharp 45% sequential recovery from ₹91 crore in Q3 to ₹132 crore.
- Operating Profit Margin remained resilient at 27%, despite intense industry price competition.
- Tax expense normalized to 17% in the current quarter compared to -1% in the previous year's base quarter.
- The balance sheet remains robust with an equity base strengthened by a bonus issue/capital injection (Equity Capital doubled).
- Full-year sales for FY26 reached ₹2,763 crore, reflecting 12% annual growth.
- The company maintained a massive cash reserve, with other assets growing to ₹1,461 crore.
- Market penetration efforts through 'SwasthFit' bundles continue to assist realization per patient.
Management Guidance
Management remains focused on driving volume growth and premiumization via Genomics and Myeloid testing while maintaining industry-leading margins through operational efficiencies.
Sentiment Shift
Improving
Outlook
The company is pivoting toward expansion in Western and Southern India to reduce geographic concentration risk, while leveraging an asset-light hub-and-spoke model for sustained profitability.
← Back to Dr. Lal Path Labs Ltd. AI analysis
Unlock the full report
Deep-dive sections, financial charts, AI chat and PDF export are available with Premium.
This summary is AI-generated from Dr. Lal Path Labs Ltd.'s latest annual report and public disclosures. It is for informational purposes only and is not investment advice.